WO2010075249A3 - A method for treating rheumatoid arthritis with b-cell antagonists - Google Patents

A method for treating rheumatoid arthritis with b-cell antagonists Download PDF

Info

Publication number
WO2010075249A3
WO2010075249A3 PCT/US2009/068917 US2009068917W WO2010075249A3 WO 2010075249 A3 WO2010075249 A3 WO 2010075249A3 US 2009068917 W US2009068917 W US 2009068917W WO 2010075249 A3 WO2010075249 A3 WO 2010075249A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
patient
treating rheumatoid
cell antagonists
cell
Prior art date
Application number
PCT/US2009/068917
Other languages
French (fr)
Other versions
WO2010075249A2 (en
Inventor
Michael J. Townsend
Zheng SU
Jay G. Wohlgemuth
Timothy W. Behrens
Preeti G. Lal
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO2010075249A2 publication Critical patent/WO2010075249A2/en
Publication of WO2010075249A3 publication Critical patent/WO2010075249A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

A method of treating rheumatoid arthritis in a patient is disclosed which comprises administering an effective amount of a B-cell antagaonist to the patient to treat the rheumatoid arthritis, provided that the rheumatoid arthritis is characterized by an elevated level of a positive acute phase protein and an elevated titer of a rheumatoid arthritis-associated autoantibody in a sample from the patient. Further provided are kits and articles of manufacture useful for such methods.
PCT/US2009/068917 2008-12-22 2009-12-21 A method for treating rheumatoid arthritis with b-cell antagonists WO2010075249A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20344208P 2008-12-22 2008-12-22
US61/203,442 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010075249A2 WO2010075249A2 (en) 2010-07-01
WO2010075249A3 true WO2010075249A3 (en) 2010-10-07

Family

ID=41786236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/068917 WO2010075249A2 (en) 2008-12-22 2009-12-21 A method for treating rheumatoid arthritis with b-cell antagonists

Country Status (1)

Country Link
WO (1) WO2010075249A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2482074A1 (en) 2011-01-27 2012-08-01 Medizinische Hochschule Hannover Methods and means for diagnosing vasculitis
GB2501611B (en) 2012-02-21 2015-03-04 Cytonics Corp Alpha-2-macroglobulin compositions and therapeutic uses
US20150202286A1 (en) * 2012-07-13 2015-07-23 The Children's Hospital of Philadelphai Toxicity Management for Anti-Tumor Activity of CARs
US9352021B2 (en) 2013-08-28 2016-05-31 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
CN113786476A (en) * 2016-12-02 2021-12-14 泰加生物工艺学公司 Nanoparticle formulations
US20210113605A1 (en) * 2017-06-20 2021-04-22 Dana-Farber Cancer Institute, Inc Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
TWI803542B (en) 2017-12-01 2023-06-01 美商艾伯維有限公司 Glucocorticoid receptor agonist and immunoconjugates thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263355A1 (en) * 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Family Cites Families (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
ES2062519T5 (en) 1989-03-21 2003-07-16 Immune Response Corp Inc VACCINATION AND METHODS AGAINST DISEASES ORIGINATED FROM PATHOGENIC RESPONSES THROUGH SPECIFIC POPULATIONS OF LYMPHOCYTES T.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DK0479909T3 (en) 1989-06-29 1997-04-07 Medarex Inc Bispecific reagents for AIDS treatment
JP3072330B2 (en) 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション T cell receptor peptides for the treatment of autoimmune and malignant diseases
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (en) 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69322860T2 (en) 1992-04-03 1999-07-01 Genentech Inc ANTIBODIES AGAINST ALPHA V BETA 3 INTEGRIN
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
DE69308573T2 (en) 1992-08-17 1997-08-07 Genentech Inc SPECIFIC IMMUNOADHESINE
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
PL174494B1 (en) 1992-11-13 1998-08-31 Idec Pharma Corp Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b
PT669986E (en) 1992-11-13 2003-08-29 Idec Pharma Corp ALTERED DOMINANT SELECTION MARKER SEQUENCE AND INTRONONIC INSERT STRATEGIES FOR IMPROVING GENERIC PRODUCT EXPRESSION AND EXPRESSION VECTOR SYSTEMS THAT UNDERSTAND IT
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
EP0771208B1 (en) 1994-08-12 2005-10-19 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP3904238B2 (en) 1996-03-20 2007-04-11 イムノメディクス， インコーポレイテッド Glycosylated humanized B cell specific antibody
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
AU7235596A (en) 1996-08-30 1998-03-19 Mayo Foundation For Medical Education And Research Hla-drb1 peptides with specific binding affinity for hla-dq molecules: prevention and treatment of rheumatoid arthritis
AU731553B2 (en) 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CA2292730C (en) 1997-06-13 2008-09-16 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1012270A2 (en) 1997-09-12 2000-06-28 Apotech R&D S.A. Kay - a novel immune system protein
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
JP4460155B2 (en) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート Humanization of mouse antibodies
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
CA2220853A1 (en) 1998-01-16 1999-07-16 Hsc Research And Development Limited Partnership Human lymphoid protein tyrosine phosphatases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ATE458007T1 (en) 1998-04-20 2010-03-15 Glycart Biotechnology Ag GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
CA2340091C (en) 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6555320B1 (en) 1998-09-01 2003-04-29 Mayo Foundation For Medical Education And Research Methods and materials for evaluating rheumatoid arthritis
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
CA2350064C (en) 1998-11-09 2012-05-08 Idec Pharmaceuticals Corporation Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
DE69942727D1 (en) 1998-11-09 2010-10-14 Biogen Idec Inc Chimeric anti-CD20 antibody, Rituxan, for use in the treatment of chronic lymphocytic leukemia
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
PL393286A1 (en) 1999-01-07 2011-06-06 Zymogenetics, Inc. Soluble BR43x2 receptor and methods for the application thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
EP1088101A4 (en) 1999-03-30 2004-10-20 Nanogen Inc Single nucleotide polymorphic discrimination by electronic dot blot assay on semiconductor microchips
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
DE05075555T1 (en) 1999-06-09 2007-02-08 Immunomedics, Inc. Immunotherapy of autoimmune diseases through the use of B cell-specific antibodies
ITMI991299A1 (en) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche USE OF ANTIBODIES AGAINST SURFACE ANTIGENS FOR THE TREATMENT OF DISEASE TRANSPLANT AGAINST GUESTS
DE19930748C2 (en) 1999-07-02 2001-05-17 Infineon Technologies Ag Method for producing EEPROM and DRAM trench memory cell areas on a chip
MXPA02000419A (en) 1999-07-12 2004-09-10 Genentech Inc Blocking immune response to a foreign antigen using an antagonist which binds to cd20.
CA2378646A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
GB9919194D0 (en) 1999-08-14 1999-10-20 Univ Leeds Genetic marker for rheumatoid arthritis
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
DE10041402A1 (en) 2000-08-23 2002-03-14 Morphochem Ag Novel compounds that inhibit factor Xa activity
JP2003508081A (en) 1999-09-08 2003-03-04 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Diagnosis and treatment methods for autoimmune diseases
US20030044420A1 (en) 1999-09-24 2003-03-06 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1231281B1 (en) 1999-11-08 2006-02-01 Eiken Kagaku Kabushiki Kaisha Method of detecting variation or polymorphism
IL149500A0 (en) 1999-11-08 2002-11-10 Idec Pharma Corp Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
WO2001062905A2 (en) 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
JP2003528155A (en) 2000-03-24 2003-09-24 カイロン コーポレイション Method for treating non-Hodgkin's lymphoma using a combination of an antibody against CD20 and interleukin-2
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN1441677A (en) 2000-03-31 2003-09-10 Idec药物公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD2O for treatment of B cell lymphoma
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
ATE375330T1 (en) 2000-04-17 2007-10-15 Ucb Pharma Sa ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES
CN1437478A (en) 2000-04-25 2003-08-20 Idec药物公司 Intrathecal administration of Rituximab for treatment of central nervous system lymphomas
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
WO2001097858A2 (en) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1172444A1 (en) 2000-07-10 2002-01-16 Conaris Research Institute GmbH Diagnostic use of polymorphisms in the gene coding for the TNF Receptor II and method for detecting non-responders to Anti-TNF therapy
KR20030031957A (en) 2000-07-12 2003-04-23 아이덱 파마슈티칼즈 코포레이션 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
HU228914B1 (en) 2000-08-18 2013-06-28 Ajinomoto Kk Phenylalanine derivatives
ATE451390T1 (en) 2000-08-18 2009-12-15 Dyax Corp POLYPEPTIDES TO BIND TO B-LYMPHOCYTE-STIMULATORY PROTEIN (BLYS)
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
CN1592645A (en) 2000-09-18 2005-03-09 拜奥根Idec公司 Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination
DE60124573T2 (en) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. NEW PHENYLALANINE DERIVATIVES
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002034790A1 (en) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
EP1407017B1 (en) 2000-11-07 2009-06-03 ZymoGenetics, Inc. Human tumor necrosis factor receptor
KR20030074693A (en) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 Crystals of whole antibodies and fragments thereof and methods for making and using them
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1268394C (en) 2001-01-17 2006-08-09 特鲁比昂药品公司 Binding domain-immunoglobulin fusion proteins
EP1373321A2 (en) 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP2004533997A (en) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Antibodies that bind both BCMA and TACI
IL157946A0 (en) 2001-04-02 2004-03-28 Genentech Inc Combination therapy
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
SK288175B6 (en) 2001-05-11 2014-04-02 Amgen Inc. Peptides and related molecules that bind to TALL-1
WO2002102312A2 (en) 2001-06-14 2002-12-27 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
WO2003010135A1 (en) 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
CN1636067A (en) 2001-08-03 2005-07-06 杰南技术公司 TACIs and BR3 polypeptides and uses thereof
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6893828B2 (en) 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
EP2131198B1 (en) 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
US7256015B2 (en) 2001-09-21 2007-08-14 Amgen Inc. TALL-1 receptor molecules and uses thereof
AU2002356858A1 (en) 2001-10-24 2003-05-06 National Jewish Medical And Research Center Structure of tall-1 and its cognate receptor
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
CN1210307C (en) 2001-11-16 2005-07-13 上海中信国健药业有限公司 Humanized anti-CD 20 monoclonal antibody
AU2002362098A1 (en) 2001-12-07 2003-06-23 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
NL1019540C2 (en) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Method for detecting autoantibodies from patients suffering from rheumatoid arthritis, peptide and assay kit.
AU2002354224A1 (en) 2001-12-13 2003-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1474451A2 (en) 2002-02-13 2004-11-10 Micromet AG De-immunized (poly)peptide constructs
CN100522999C (en) 2002-02-14 2009-08-05 免疫医疗公司 Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
ATE464299T1 (en) 2002-02-20 2010-04-15 Ajinomoto Kk NEW PHENYLALANINE DERIVATIVE
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003301445A1 (en) 2002-10-17 2004-05-04 Genmab A/S Human monoclonal antibodies against cd20
CA2507882A1 (en) 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
ES2633311T3 (en) 2002-12-16 2017-09-20 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
PL1613350T3 (en) 2003-04-09 2009-08-31 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
JP5416338B2 (en) 2003-05-09 2014-02-12 デューク ユニバーシティ CD20-specific antibody and method of use thereof
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
BRPI0411276A (en) 2003-06-05 2006-08-01 Genentech Inc B-cell depletion methods, B-cell neoplasm or malignancy treatment method, B-cell-regulated autoimmune dysfunction relief method, composition and industrialized article
EP1649062B1 (en) 2003-07-03 2009-12-09 Gentron, LLC. Methods and systems for diagnosis of non-central nervous system (cns) diseases in cns samples
US20050059479A1 (en) 2003-07-25 2005-03-17 Bally Gaming International, Inc. Uniquely identifiable casino gaming chips
CN1860367B (en) 2003-07-29 2010-05-26 健泰科生物技术公司 Assay for human anti cd20 antibodies and uses therefor
CN100584858C (en) 2003-08-07 2010-01-27 弗·哈夫曼-拉罗切有限公司 RA antigenic peptides
EP1651663B1 (en) 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
JP2007504138A (en) 2003-08-29 2007-03-01 ジェネンテック・インコーポレーテッド Treatment of eye diseases
EP1664796B1 (en) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
ME03330B (en) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
US20050136044A1 (en) 2003-12-04 2005-06-23 Watkins Jeffry D. Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
US20050186206A1 (en) 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
AU2004303848A1 (en) 2003-12-19 2005-07-07 Genentech, Inc. Detection of CD20 in transplant rejection
DK1882946T3 (en) 2003-12-23 2010-05-31 Hoffmann La Roche Method for Assessing Rheumatoid Arthritis by Measuring Anti-CCP and Interleukin 6
EP2154157A3 (en) 2004-01-12 2010-04-28 Applied Molecular Evolution Inc. FC region variants
WO2005085859A1 (en) 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
JP4495208B2 (en) 2004-02-27 2010-06-30 エフ．ホフマン−ラ ロシュ アーゲー Method for evaluating rheumatoid arthritis by measuring anti-CCP and serum amyloid A
WO2005086872A2 (en) 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
EP1745288A2 (en) 2004-04-16 2007-01-24 Genentech, Inc. Assay for antibodies
KR20070012408A (en) 2004-04-16 2007-01-25 제넨테크, 인크. Method for augmenting b cell depletion
RU2006140374A (en) 2004-04-16 2008-05-27 Дженентек, Инк. (Us) TREATMENT OF VIOLATIONS
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
RU2006142857A (en) 2004-05-05 2008-06-10 Дженентек, Инк. (Us) PREVENTION OF AUTOIMMUNE DISEASE
US20060008823A1 (en) 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
WO2005114218A2 (en) 2004-05-15 2005-12-01 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
US20050266410A1 (en) 2004-05-19 2005-12-01 Emily Walsh Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
KR20130099228A (en) 2004-06-04 2013-09-05 제넨테크, 인크. Method for treating multiple sclerosis
CA2568336A1 (en) 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
US20080199514A1 (en) 2004-07-09 2008-08-21 The Burnham Institute Functional Variant of Lymphoid Tyrosine Phosphatase is Associated with Autoimmune Disorders
MX2007000327A (en) 2004-07-09 2007-03-12 Schering Ag Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma.
WO2006014725A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlcNAcMAN5GLCNAC2 GLYCOFORM
CA2573842A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
WO2006014679A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
JP2008512354A (en) 2004-07-21 2008-04-24 グライコフィ， インコーポレイテッド Immunoglobulin containing predominantly Man3GlcNAc2 glycoform
AU2005269713A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GlcNac2 glycoform
BRPI0513100A (en) 2004-07-22 2007-10-23 Genentech Inc methods of treating sjígren's syndrome and manufactured articles
EP1774328A1 (en) 2004-07-23 2007-04-18 Novartis AG Biomarkers for rheumatoid arthritis (ra)
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
BRPI0515230A (en) 2004-08-19 2008-07-15 Genentech Inc isolated polypeptides, antibodies and nucleic acids, compositions, expression vector, isolated host cells, method of producing an antibody, manufactured articles, methods of treatment and alleviating dysfunction, methods of making and selecting a polypeptide, antibody cd20 binding agent, isolated anti-her2 antibody and uses of an antibody
ES2911482T3 (en) 2004-09-03 2022-05-19 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
BRPI0515615A (en) 2004-09-08 2008-07-29 Genentech Inc Methods to Treat Cancer Cells and Related Immune Disease
AU2005294666A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
GT200500283A (en) 2004-10-08 2006-05-08 IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
FR2879204B1 (en) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
JP2008524241A (en) 2004-12-17 2008-07-10 ジェネンテック・インコーポレーテッド Anti-angiogenic treatment of autoimmune disease in patients who have not had the effect of conventional treatment
CN1796997A (en) 2004-12-22 2006-07-05 上海富纯中南生物技术有限公司 Detection kit for diagnosing RA, preparating kit, and method for completing standard of quality detection
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
US20060188495A1 (en) 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
US8101179B2 (en) 2005-03-31 2012-01-24 Biomedics Inc. Anti-CD20 monoclonal antibody
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
DE602006012839D1 (en) 2005-05-20 2010-04-22 Genentech Inc PRE-TREATMENT OF A BIOLOGICAL SAMPLE FROM AN INDIVIDUAL WITH AUTOIMMUNE DISEASE
CA2609731A1 (en) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd. A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
CN101282993A (en) 2005-06-02 2008-10-08 阿斯利康公司 Antibodies directed to cd20 and uses thereof
WO2007000169A2 (en) 2005-06-29 2007-01-04 Genmab A/S Non-human mammalian arthritis model featuring human antibodies against citrullinated proteins
CN1290864C (en) 2005-07-11 2006-12-20 中国人民解放军军事医学科学院生物工程研究所 Ant CD20 chimeric antibody
CN101267836A (en) 2005-07-25 2008-09-17 特鲁比昂药品公司 Single dose use of CD20-specific binding molecules
PL1912675T3 (en) 2005-07-25 2014-10-31 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
CN101262876A (en) 2005-08-09 2008-09-10 酶遗传学股份有限公司 Methods for treating B-cell malignancies using a TACI-IG fusion molecule
US7723036B2 (en) 2005-08-18 2010-05-25 The University Of Iowa Research Foundation Assessing response to anti-CD20 therapy by genotyping C1q components
US7935482B2 (en) 2005-09-27 2011-05-03 Source Precision Medicine, Inc. Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130004480A1 (en) 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263355A1 (en) * 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ICHIKAWA Y ET AL: "Molecular markers of coagulation and fibrinolysis as indicators for the disease activity of rheumatoid arthritis", JAPANESE JOURNAL OF RHEUMATOLOGY 1997 NL, vol. 7, no. 3, 1997, pages 173 - 181, XP002572948, ISSN: 0169-1163 *
KUHN E ET AL: "QUANTIFICATION OF C-REACTIVE PROTEIN IN THE SERUM OF PATIENTS WITH RHEUMATOID ARTHRITIS USING MULTIPLE REACTION MONITORING MASS SPECTROMETRY AND 13C-LABELED PEPTIDE STANDARDS", PROTEOMICS, WILEY - VCH VERLAG, WEINHEIM, DE, vol. 4, no. 4, 1 April 2004 (2004-04-01), pages 1175 - 1186, XP009039539, ISSN: 1615-9853 *
OLIGINO THOMAS J ET AL: "Targeting B cells for the treatment of rheumatoid arthritis.", ARTHRITIS RESEARCH & THERAPY 2003, vol. 5 Suppl 4, 2003, pages S7 - 11, XP002572947, ISSN: 1478-6362 *

Also Published As

Publication number Publication date
WO2010075249A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010075249A3 (en) A method for treating rheumatoid arthritis with b-cell antagonists
WO2009137832A3 (en) Autoantibodies in the detection and treatment of cancer
HUS1600044I1 (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
WO2006076651A3 (en) Treatment method
ZA201105136B (en) Method for treating water by ballasted flocculation and settlement,including pre-contacting the water with an adsorbent
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
HK1204994A1 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
MX2010009722A (en) Methods of treating chronic pain.
WO2013058833A8 (en) Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2012106556A3 (en) Methods and compositons relating to inhibition of igf-1r
WO2009134710A3 (en) Methods for enhancing utrophin production via inhibition of microrna
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
MX2009008608A (en) Monoclonal anti-cxcl13 antibodies.
EP2290370B8 (en) Method for determining cause of the prolongation of blood coagulation time
WO2009064938A9 (en) Method of treating arthritis
WO2009041009A1 (en) Method and apparatus for treatment of organic waste
IL212416A0 (en) Method for multimedia content search on the internet
WO2009138408A3 (en) Methods and kits for the diagnosis of rheumatoid arthritis
PT2131181T (en) Method for the determination of the total acid number and naphthenic acid number of petroleum, petroleum cuts and petroleum emulsions of water-in-oil type by mid-infrared spectroscopy
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2011139820A8 (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EA201201113A1 (en) METHODS AND CONNECTIONS FOR GROWTH OF MUSCLE
WO2010077327A3 (en) System, method, or apparatus for updating stored search result values
WO2011130347A3 (en) Methods for enhancing axonal regeneration
SI2235060T1 (en) B-cell depleting agents, like anti-cd20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09798992

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09798992

Country of ref document: EP

Kind code of ref document: A2